Jan
20
2022
On demand

Professionalizing mesenchymal stem cells for therapeutic benefit

While mesenchymal stem cells (MSC) clinical trials were first initiated several decades ago, the promise of globally approved MSC products for a myriad of indications has not been delivered. We now have the ability to generate MSCs from other sources, such as induced pluripotent stem cells (iPSCs) and to perform gene modifications that enhance specific functions or to allow escape from immune recognition that will lead to the development of professionalized MSCs.

This webinar will discuss the need for cell therapies to continue optimization from sourcing to therapeutic effect and the strategies to improve their development and production.

Discover more about:

  • Enhancing the therapeutic effects to overcome early limitations of MSC therapies in several indications 
  • Strategies to develop the next generation of targeted and robust MSC treatments 
  • The need for continued optimization of the sourcing and manufacturing of allogeneic MSC therapeutics

Anthony Ting, PhD

Chief Scientific Officer, Bone Therapeutics

Dr. Ting brings to Bone Therapeutics over 30 years of academic and industry experience in translational science and global regulatory filing, and 20 years specifically in stromal cell-based therapeutics. He is currently the Chief Commercialization Officer on the board of directors for the International Society for Cell and Gene Therapy (ISCT) and is serving on Science and Technology committee for the Alliance for Regenerative Medicine (ARM).

Most recently, Dr. Ting served in the senior management team of Athersys, a Nasdaq-listed clinical-stage cell therapy company. As Vice President of Regenerative Medicine and Head of Cardiopulmonary Programs, he was responsible for all stages of development, from the bench to the bedside for the cardiovascular and pulmonary programs with Athersys’ most advanced cell therapy product MultiStem®, an allogeneic adult bone marrow-derived stem cell product. Prior to joining Athersys, Dr. Ting was a Principal Investigator and Head of the Novel Inhibitors Screening Group at the Institute of Molecular and Cell Biology (IMCB) at the National University of Singapore, which identified new therapeutic targets through high-throughput screening. Dr. Ting received his PhD in Cell Biology from Johns Hopkins University and his B.A. in Biology from Amherst College.


SPEAKERS

Anthony Ting
Chief Scientific Officer at Bone Therapeutics

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
35
Days
0
Hrs
13
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
0
Hrs
13
Min
Register

Monitoring of circulating CAR T cells

A Graband,
D Hünecke,
D Bremm
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
Dr. Sabine Hünecke
Dr. Sabine Hünecke
Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
Dr. Melanie Bremm
Dr. Melanie Bremm
Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
31 May 2022
13
Days
0
Hrs
13
Min
Register

Improving T cell therapy manufacturing processes with automation and...

E Zynda, PhD
Evan Zynda, PhD
Evan Zynda, PhD
Staff Scientist, Cell Biology at Thermo Fisher Scientific
26 May 2022
8
Days
0
Hrs
13
Min
Register

Streamlined workflow solutions for cell and gene therapy analytics

A Graband
Annika Graband
Annika Graband
Product Manager, Cell Analysis Reagents at Miltenyi Biotec
24 May 2022
6
Days
0
Hrs
13
Min
Register